Clinical Study Results.org is an excellent site for finding out what is going on with drug company research and provides clinical study results in a “reader friendly standardized format” to make the results for many marketed pharmaceuticals more transparent. ”
- The A.I.M.M Trial. A Phase 3 clinical study for Allovectin-7. “The purpose of the A.I.M.M. Trial is to find out whether Allovectin-7® works better than standard chemotherapy for people with Stage 3 or Stage 4 melanoma.” Per the NCI site, “Allovectin -7 is a substance that is being studied as a gene therapy in the treatment of cancer. It increases the ability of the immune system to recognize cancer cells and kill them.
- OVATURE (Ovarian Tumor Response) A research opportunity for women with recurrent ovarian cancer. ” Patients in the trial will receive an experimental treatment regimen consisting of weekly carboplatin. Half of the patients in the trial will also receive the investigational drug phenoxodiol. The other half will receive a placebo so that neither researchers nor patients can tell which arm of the trial the patient is in.” See the Novogen site for more information on phenoxodiol known as multiple signal transduction regulators (MSTRs).
- The SPRAY Study. A study of Sativex for pain relief in patients with advanced malignancy. The Phase II trial is currently recruiting patients. “The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex in patients with advanced cancer, who experience inadequate pain relief even though they are on optimized chronic opioid therapy.” For more information see the Center Watch, Clinical Trials Listing Service site.
April 15, 2008 the National Cancer Institute posts the positive results of a five year study of adenoma prevention with Celecoxib. Celecoxib Reduces Risk of Precancerous Colorectal Polyps: Five-Year Results of APC Trial.
ScienceDaily, April 8, 2008. Randomized Clinical Trial Results on Preoperative Chemotherapy in Early Breast Cancer. “Eight cycles of preoperative chemotherapy was no better than six cycles in women with early breast cancer who had responded to two initial cycles, according to data from a randomized controlled trial.”